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Abstract
Background
Increased second-line antiretroviral therapy (ART) failure rate narrows future options for
HIV/AIDS treatment. It has critical implications in resource-limited settings; including sub-
Saharan Africa (SSA) where the burden of HIV-infection is immense. Hence, pooled esti-
mate for second-line HIV treatment failure is relevant to suggest valid recommendations
that optimize ART outcomes in SSA.
Methods
We retrieved literature systematically from PUBMED/MEDLINE, EMBASE, CINAHL, Goo-
gle Scholar, and AJOL. The retrieved studies were screened and assessed for eligibility. We
also assessed the eligible studies for their methodological quality using the Joanna Briggs
Institute’s appraisal checklist. The pooled estimates for second-line HIV treatment failure
and its associated factors were determined using STATA, version 15.0 and MEDCALC, ver-
sion 18.11.3, respectively. We assessed publication bias using Comprehensive Meta-analy-
sis software, version 3. Detailed study protocol for this review/meta-analysis is registered
and found on PROSPERO (ID: CRD42018118959).
Results
A total of 33 studies with the overall 18,550 participants and 19,988.45 person-years (PYs)
of follow-up were included in the review. The pooled second-line HIV treatment failure rate
was 15.0 per 100 PYs (95% CI: 13.0–18.0). It was slightly higher at 12–18 months of follow-
up (19.0/100 PYs; 95% CI: 15.0–22.0), in children (19.0/100 PYs; 95% CI: 14.0–23.0) and
in southern SSA (18.0/100 PYs; 95% CI: 14.0–23.0). Baseline values (high viral load (OR:
5.67; 95% CI: 13.40–9.45); advanced clinical stage (OR: 3.27; 95% CI: 2.07–5.19); and low
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CD4 counts (OR: 2.80; 95% CI: 1.83–4.29)) and suboptimal adherence to therapy (OR:
1.92; 95% CI: 1.28–2.86) were the factors associated with increased failure rates.
Conclusion
Second-line HIV treatment failure has become highly prevalent in SSA with alarming rates
during the 12–18 month period of treatment start; in children; and southern SSA. Therefore,
the second-line HIV treatment approach in SSA should critically consider excellent adher-
ence to therapy, aggressive viral load suppression, and rapid immune recovery.
Introduction
In the past decade, rapid scale-up of antiretroviral therapy (ART) in sub-Saharan Africa (SSA)
substantially reduced HIV/AIDS-related morbidity and mortality [1, 2]. It has also prolonged
the average life expectancy of HIV-infected individuals [1]. However, these benefits are being
challenged by the increasing HIV treatment failure rates with first or second-line antiretroviral
therapies [3–6]. HIV treatment failure can be defined in terms of clinical, immunological, or
virological failures [7]. Clinical failure is the occurrence of a new or recurrent stage III or stage
IV clinical event (s). Immunological failure is the decline of CD4 counts either to less than the
pre-treatment value or to<50% of a peak value on ART or persistently lower than 100 cells/ml
[7]. Virological failure could be a definite failure (i.e., when a single viral load (VL) is greater
than 10,000 copies/ml at 12 months of follow-up) or a probable failure (i.e., when either a sin-
gle VL is >1000 copies/ml at 12 months or a VL at 12 months is� 400 copies/ml confirmed
by a second measurement taken 30 days later) [8–10]. Clinical and immunological failure cri-
teria are not sufficient for the definite diagnosis of treatment failure and each of them should
be accompanied with VL tests as a confirmation [11]. With this, VL testing is efficient to indi-
cate direct plasma effects of ART on HIV ribonucleic acid (RNA) [12]. It also helps preserve
the limited HIV treatment options available by reducing the probability of incorrect switching
to the next more expensive and toxic regimens [13].
The HIV-infected patients on ART are recalling earlier fears of death from the infection
because of treatment failures [14]. Patients who experienced first-line HIV treatment failure
may be switched to second-line regimens [15, 16]. Many countries in resource-limited settings
switch a failed first-line ART to second-line regimen after an initial delay mainly related to
inadequate VL tests [11]. The inadequacy of VL informed differentiated care for the HIV-
infected patients commenced with second-line ART [17] could increase the risks of death and
opportunistic infections especially in patients with advanced HIV at the time of first-line HIV
treatment failure [18].
The HIV treatment failure involving second-line regimens has very narrow options for fur-
ther switching, and this is a serious concern in resource-limited settings [19]. The World
Health Organization (WHO) recommends few second-line regimens as preferred ART (i.e.,
ritonavir-boosted atazanavir- or lopinavir-based ART and dolutegravir-based ART) [20, 21].
Despite the limited second-line HIV treatment options, many countries in SSA have financial
constraints to adopt third-line regimens [20, 21]. As a result, the optimal use of second-line
therapies after the occurrence of first-line HIV treatment failure is alarmingly essential for
SSA, the epicenter of HIV/AIDS. However, many countries in SSA have no national strategic
guidelines for the optimal use of second-line therapy despite the occurrence of a number of
treatment failures related to the therapies [17].
Second-line HIV treatment failure rates in SSA
PLOS ONE | https://doi.org/10.1371/journal.pone.0220159 July 29, 2019 2 / 19
Africa; VL, Viral Load; WHO, World Health
Organization.
Suboptimal adherence (i.e., missing of any dose in the past 3 days [22] or 7 days [23]; or less
than 95% adherence in the past 30 days [24] or less than 90% adherence in the past year [25])
was indicated as a key determinant of second-line HIV treatment failure [26, 27]. Suboptimal
adherence could be a result of regimen toxicities [28]. It may require a tailored adherence
intervention based on the degree of suboptimal adherence [27, 29]. Baseline characteristics
such as delayed initiation of second-line therapy [30] and high VL might result in unfavorable
treatment outcomes [25]. To maximize the durability of the second-line regimens, early identi-
fication of first-line treatment failure and switching to a second-line regimen at a relatively
higher CD4 cell count is very important [31, 32]. Advanced clinical stage at baseline and lack
of VL monitoring were also identified to have associations with second-line HIV treatment
failures [33]. In addition, the clinical status of patients such as baseline clinical stage IV and
CD4 counts below 100 cells/mm3 were significantly linked with increased rates of treatment
failure [34]. As a result, pooling the proportion of second-line HIV treatment failures and fac-
tors associated with these failures are required to assist the optimization of HIV treatment out-
comes in SSA. Therefore, the aim of this systematic review and meta-analysis was to estimate
the proportion of second-line HIV treatment failure and its associated factors in SSA.
Materials and methods
Study protocol
The method of this systematic review and meta-analysis was reported as per the Preferred
Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 state-
ment recommendations [35]. Identification of records, screening by titles and abstracts, and
eligibility evaluation of full texts for final inclusion was conducted in accordance with the
PRISMA flow diagram [36]. During the execution of this systematic review and meta-analysis,
the PRISMA checklist was strictly followed. The protocol is registered on the International
Prospective Register of Systematic Reviews (PROSPERO) with a registration number of
CRD42018118959 and it is available at https://www.crd.york.ac.uk/prospero/#recordDetails.
php?ID=CRD42018118959 [37].
Data sources and searches
We performed a systematic literature search from PubMed, MEDLINE (Ovid), EMBASE
(Ovid), CINAHL (EBSCOhost), Cochrane Library, Google Scholar, Health Technology
Assessment, African Journals Online (AJOL) and ResearchGate. Websites of organizations
and University repositories were also visited to retrieve any remaining relevant record includ-
ing unpublished (gray) kinds of literature. In our search strategy, search terms we employed
were “treatment failure”; “second-line”; “protease inhibitor”; “antiretroviral therapy”; and
names of countries in the SSA. During the search, we accomplished a careful selection of key-
words and indexing terms that did not limit the year of publication. In the search strategy,
Boolean operators and truncations were also employed. The search was conducted from 15
December 2018 to 14 January 2019. Accordingly, all published and unpublished literature
identified during the period of searching were retrieved.
Study selection
We set predefined inclusion and exclusion criteria for initial screening by titles or abstracts
and evaluation of full texts for their eligibility assessment. We considered articles with at least
an outcome of failure to second-line ART for their potential to be included. Next, we assessed
the original articles reporting second-line HIV treatment failure after at least 6 month period
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of follow-up; reported in English language; and conducted in countries of SSA for their eligi-
bility. In addition, we assessed the eligible original articles for quality using the Joanna Briggs
Institute’s (JBI) critical appraisal checklist and articles with moderate (50–75%) to high
(>75%) quality were considered as per the appraisers’ evaluation results. However, we
excluded articles with outcomes not related to second-line therapy failure; with no separate
failure data for SSA patients in case of mixed multi-center study settings involving SSA and
other countries; and with no separate data of second-line therapy failure in studies involving
first and second-line therapies during the screening and eligibility assessments.
Screening and eligibility
We identified and selected records retrieved through a search of the electronic databases and
indexing services. Following this, we exported them to ENDNOTE reference software version
8.2 (Thomson Reuters, Stamford, CT, USA). Next, we identified, registered, and removed
duplicates by the use of ENDNOTE. Accordingly, two authors, Dumessa Edessa (DE) and
Mekonnen Sisay (MS), independently screened titles and abstracts of the retained records
based on the predefined inclusion criteria. A third author, Fekede Asefa (FA), was consulted in
case of disagreement between the two authors. With this, DE and FA individually collected
and evaluated full texts of the retained articles for their quality and final eligibility assessment.
In the end, we included articles that fulfilled the quality evaluation criteria.
Quality assessment and data extraction
We accomplished quality assessment for the articles by employing the JBI’s critical appraisal
checklist for cohort and analytical cross-sectional studies [38, 39]. Two authors (DE and MS)
critically appraised the articles. For the final decision of inclusion, we considered scores of the
two authors in consultation with the third author’s score (in case of disagreement between the
two authors’ appraisal results). Lastly, we ranked the articles by their methodological qualities
based on the total number of appraisers’ score marked as ‘yes’ to questions of the JBI’s critical
appraisal checklist. Accordingly, we included all studies with their overall positive responses in
ranges of 50% to 75% (moderate quality studies) or higher than 75% (high quality studies) for
the review and meta-analysis.
To extract relevant data, we employed a customized data abstraction format that has been
prepared in a Microsoft Excel sheet. Two of the authors independently abstracted data pertain-
ing to first author; year of publication; study design (analytical cross-sectional, follow-up);
study region/country; study participants (children, adults, mixed-age groups); types of second-
line ART (ritonavir-boosted protease inhibitor (PI)-based ART, PI-based ART with no ritona-
vir-boosting); sample size; median months of follow-up; person/patient-years (PYs) of follow-
up; and event of interest (number of second-line therapy failure and factors associated with
the failure).
Outcome variables
Proportion of second-line HIV treatment failure that includes clinical, immunological or viro-
logical failure, as defined by the WHO [7, 9] was the primary outcome variable we estimated
in this systematic review and meta-analysis. The secondary outcome measure we estimated
was factors associated with the second-line HIV treatment failures.
Second-line HIV treatment failure rates in SSA
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Data synthesis and analysis
Proportion of second-line HIV treatment failure we pooled together was accomplished with
the help of STATA software, version 15.0. Again, we performed sensitivity and subgroup anal-
yses to minimize the risks of bias. With this, we used forest plots to graphically report the vari-
ous meta-analysis results. We also applied the Mantel-Haenszel random-effects model to
conduct meta-analyses at a 95% confidence level. Likewise, we assessed the heterogeneity sta-
tus of the included studies and presented it with the use of Cochran’s Q test (chi-squared (I2)
statistic). We also accomplished tests for factors associated with second-line therapy failure by
using MEDCALC statistical software (MedCalc Software bvba, Ostend, Belgium), version
18.11.3. Besides, we employed Comprehensive Meta-analysis software (Biostat, Englewood,
New Jersey, USA), version 3, for publication bias assessment. Similarly, we evaluated the pres-
ence of publication bias with the use of Egger’s regression and Begg’s correlation tests. Lastly,
we considered all statistical tests with p-values less than 0.05 (two-tailed) as significant.
Results
We identified a total of 1,608 records from the search of legitimate databases and indexing ser-
vices. After the removal of 368 duplicates, we retained 1240 records for screening by titles and
abstracts. Again, we excluded a total of 1,142 literature by screening titles (n = 294) and
abstracts (n = 848). Of this 1,142 literature, 947 of them had unrelated outcomes of interest; 73
of them were discussion papers; 72 of them had outcomes of first-line therapy failure; 46 of
them had mixed and/or other country studies, and 4 of them reported their outcomes with
non-English languages. Accordingly, we conducted an eligibility evaluation of 98 full texts as
per the predefined eligibility criteria for inclusion. Again, we excluded 65 studies with justifi-
able reasons (i.e., 56 of them with irrelevant/insufficient outcomes of interest; 9 of them with
mixed first and second-line HIV treatment failures and no separate data for second-line ther-
apy failure). PRISMA flow chart depicting the selection, screening, and eligibility assessment
process is shown in Fig 1 and S1 Table. We also assessed these records for their methodological
quality by employing the JBI’s critical appraisal checklists (Table 1). Finally, we included 33
articles with the primary outcome of interest and with a high or moderate percentage in its
score of methodological quality assessment for the systematic reviews and meta-analysis.
Study characteristics
The 33 studies included for the systematic reviews and meta-analysis had a total of 18,550 par-
ticipants, and 2,473 of them experienced treatment failures to their second-line HIV treatment.
The study participants had a total of 19,988.45 PYs of follow-up. All the included studies were
published during the year 2009 to 2018. Sample sizes for the included studies range from 40
patients enrolled by a study conducted in Uganda [40] to 6,714 patients enrolled by a study
accomplished in Nigeria [41]. The study participants of 26 studies were adults [19, 23–25, 27,
34, 40, 42–60], while that of 2 studies [22, 61] and 5 studies [6, 41, 62–64] were children and
mixed age groups, respectively. Sixteen studies (n = 16) were from southern Africa [23, 27, 43,
45–52, 57, 58, 60, 62, 64]; 7 studies were from eastern Africa [22, 34, 40, 53, 55, 61, 63]; 5 stud-
ies were from western Africa [25, 41, 42, 44, 54]; and 5 studies were from mixed regions in SSA
[6, 19, 24, 55, 59]. The second-line HIV treatment regimens received by the study participants
were PI-based, 18 of them with ritonavir-boosted PI-based ART [24, 25, 27, 40, 42, 44, 45, 48,
49, 52–56, 58, 60, 61, 63] and 15 of them with no ritonavir in their PI-based ART regimens [6,
19, 22, 23, 34, 41, 43, 46, 47, 50, 51, 57, 59, 62, 64]. Thirteen studies (n = 13) defined the sec-
ond-line HIV treatment failure by using the WHO definition of RNA VL more than 400 cop-
ies/ml [6, 19, 24, 25, 27, 42, 47, 49, 53, 54, 56–58] while 16 of the studies employed the WHO
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criteria of HIV RNA VL above 1000 copies/ml [22, 23, 40, 43–46, 48, 50–52, 55, 59–61, 63].
However, 4 of the studies employed mixed definitions of the WHO criteria for ART failure
that included clinical, immunological and virological failures and/or death/lost to follow-up
[34, 41, 62, 64] (Table 2 and S2 Table).
Proportion of patients with second-line ART failure
The pooled estimate for rate of second-line HIV treatment failure was 15.0 per 100 PYs of fol-
low-up (95% CI: 13.0–18.0 per 100 PYs; I2 = 97.69%; P<0.001). The second-line treatment
Fig 1. PRISMA flow diagram depicting the selection process.
https://doi.org/10.1371/journal.pone.0220159.g001
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failures among the included studies range from 1.0/100 PYs (95% CI: 0.0–3.0 per 100 PYs) to
40.0/100 PYs (95% CI: 30.0–50.0) (Fig 2).
Table 1. Quality assessment for included studies.
References JBI’s Critical Appraisal Checklist
Q1 Q2 Q3 Q4 Q5 Q6 Q7 Q8 Q9 Q10 Q11
Adetunji et al, 2013 NA NA Yes Yes Yes Yes Yes Yes UC No Yes
Akanmu et al, 2015 NA NA Yes Yes Yes Yes Yes Yes UC No Yes
Berhanu et al, 2014 NA NA Yes No No Yes Yes Yes Yes No Yes
Boender et al, 2016 NA NA Yes Yes Yes Yes Yes Yes Yes Yes Yes
Boerma et al, 2017 NA NA Yes No No Yes Yes Yes Yes No Yes
Castelnuovo et al, 2009 NA NA Yes No No Yes Yes Yes Yes No Yes
Ciaffi et al, 2015 NA NA Yes Yes Yes Yes Yes Yes Yes Yes Yes
Collier et al, 2017 NA NA Yes Yes Yes Yes Yes Yes Yes No Yes
Court et al, 2014 NA NA Yes Yes Yes Yes Yes Yes No No Yes
Evans et al, 2018 NA NA Yes Yes Yes No Yes Yes No No Yes
Evans et al, 2018 NA NA Yes Yes Yes No Yes Yes No No Yes
Fox et al, 2010 NA NA Yes Yes Yes Yes Yes Yes Yes No Yes
Fox et al, 2016 NA NA Yes No No Yes Yes Yes Yes No Yes
Garone et al, 2013 NA NA Yes Yes Yes Yes Yes Yes Yes Yes Yes
Hosseinipour et al, 2010 NA NA Yes Yes Yes Yes Yes Yes Yes No Yes
Johnston et al, 2012 NA NA Yes Yes Yes Yes Yes Yes Yes No Yes
Johnston et al, 2014 NA NA Yes Yes Yes Yes Yes Yes Yes No Yes
Levison et al, 2012 NA NA Yes No No Yes Yes Yes Yes No Yes
Murphy et al, 2012 NA NA Yes Yes Yes Yes Yes Yes Yes No Yes
Musiime et al, 2013 NA NA Yes Yes Yes Yes Yes Yes Yes No Yes
Ongubo et al, 2017 NA NA Yes Yes Yes Yes Yes Yes No No Yes
Onyedum et al, 2013 NA NA Yes No No Yes Yes Yes Yes No Yes
Paton et al, 2014 NA NA Yes Yes Yes Yes Yes Yes Yes Yes Yes
Paton et al, 2017 NA NA Yes Yes Yes Yes Yes Yes Yes Yes Yes
Pujades et al, 2010 NA NA Yes Yes Yes Yes Yes Yes Yes No Yes
Rawizza et al, 2013 NA NA Yes No No Yes Yes Yes Yes Yes Yes
Schoffelen et al, 2013 NA NA Yes Yes Yes Yes Yes Yes Yes No Yes
Shearer et al, 2017 NA NA Yes Yes Yes Yes Yes Yes Yes No Yes
Sigaloff et al, 2012 NA NA Yes Yes Yes Yes Yes Yes Yes No Yes
Tsegaye et al, 2016 NA NA Yes Yes Yes Yes Yes Yes Yes No Yes
Wandeler et al, 2012 NA NA Yes Yes Yes Yes Yes Yes Yes No Yes
Wandeler et al, 2014 NA NA Yes Yes Yes Yes Yes Yes Yes No Yes
Van Zyl et al, 2011 Yes Yes Yes Yes Yes No Yes Yes
Note: NA, not applicable; UN, unclear; Q1-8, JBI’s Critical Appraisal Checklist for Analytical Cross Sectional studies {Q1: Were the criteria for inclusion in the sample
clearly defined? Q2: Were the study subjects and the setting described in detail? Q3: Was the exposure measured in a valid and reliable way? Q4: Were objective,
standard criteria used for measurement of the condition? Q5: Were confounding factors identified? Q6: Were strategies to deal with confounding factors stated? Q7:
Were the outcomes measured in a valid and reliable way? Q8: Was appropriate statistical analysis used?}; Q1-11, JBI’s Critical Appraisal Checklist for Cohort studies
{Q1: Were the two groups similar and recruited from the same population? Q2: Were the exposures measured similarly to assign people to both exposed and unexposed
groups? Q3: Was the exposure measured in a valid and reliable way? Q4: Were confounding factors identified? Q5: Were strategies to deal with confounding factors
stated? Q6: Were the groups/participants free of the outcome at the start of the study (or at the moment of exposure)? Q7: Were the outcomes measured in a valid and
reliable way? Q8: Was the follow up time reported and sufficient to be long enough for outcomes to occur? Q9: Was follow up complete, and if not, were the reasons to
loss to follow up described and explored? Q10: Were strategies to address incomplete follow up utilized? Q11: Was appropriate statistical analysis used?}.
https://doi.org/10.1371/journal.pone.0220159.t001
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Table 2. Characteristics of studies describing second-line ART failure among patients on treatment follow-up in sub-Saharan Africa.
References Year of
publication
Study
design
Study setting Patient
groups
Second-line
regimen
Sample
size
Number
with TF
PYs of
follow-up
Adetunji et al
[25]
2013 RFU Nigeria Adults PI/r-based 225 34 225
Akanmu et al
[42]
2015 RFU Nigeria Adults LPV/r-based 318 25 636
Berhanu et al
[43]
2014 RFU South Africa Adults PI-based 372 129 465
Boender et al
[19]
2016 FU Zambia, South Africa, Kenya, Uganda, Zimbabwe
and Nigeria
Adults PI-based 227 32 227
Boerma et al
[22]
2017 FU Uganda Children PI-based 60 12 120
Castelnuovo et al
[40]
2009 FU Uganda Adults LPV/r-based 40 7 120
Ciaffi et al [44] 2015 FU Cameroon, Senegal and Burkina Faso Adults PI/r-based 451 5 451
Collier et al [45] 2017 FU South Africa Adults LPV/r-based 101 23 202
Court et al [46] 2014 RFU South Africa Adults PI-based 228 26 228
Evans et al [23] 2018 RFU South Africa Adults PI-based 128 50 192
Evans et al [47] 2018 RFU South Africa Adults PI-based 719 36 1438
Fox et al [49] 2010 FU South Africa Adults PI-based 262 59 262
Fox et al [48] 2016 FU South Africa Adults LPV/r-based 388 106 446.6
Garone et al [62] 2013 FU South Africa Mixed-age
groups
PI-based 40 7 30
Hosseinipour
et al [63]
2010 FU Malawi Mixed-age
groups
LPV/r-based 101 15 101
Johnston et al
[50]
2014 FU South Africa Adults PI-based 122 39 518.75
Johnston et al
[51]
2012 FU South Africa Adults LPV/r-based 417 43 152.5
Levison et al [52] 2012 RFU South Africa Adults LPV/r-based 322 43 268.3
Murphy et al
[27]
2012 FU South Africa Adults LPV/r-based 136 26 136
Musiime et al
[61]
2013 FU Uganda Children LPV/r-based 142 55 142
Ongubo et al
[53]
2017 RFU Malawi Adults ATV/r-
based
376 35 282
Onyedum et al
[54]
2013 RFU Nigeria Adults LPV/r-based 68 12 68
Paton et al [55] 2014 FU Five countries in SSA Adults LPV/r-based 379 35 758
Paton et al [56] 2017 FU Malawi, Uganda, Zimbabwe and Kenya Adults LPV/r-based 336 45 1008
Pujades et al [6] 2010 FU Burkina Faso, Democratic Republic of Congo,
Kenya, Malawi, Mozambique, Nigeria, Zimbabwe,
South Africa, Uganda, Zambia
Mixed-age
groups
PI-based 493 91 493
Rawizza et al
[41]
2013 RFU Nigeria Mixed-age
groups
PI-based 6714 673 3357
Schoffelen et al
[64]
2013 RFU South Africa Mixed-age
groups
PI-based 191 48 318.3
Shearer et al [57] 2017 RFU South Africa Adults PI-based 927 233 927
Sigaloff et al [24] 2012 FU Uganda, South Africa, Kenya, Nigeria, Zambia and
Zimbabwe
Adults PI/r-based 232 63 232
Tsegaye et al
[34]
2016 RFU Ethiopia Adults PI-based 356 67 712
(Continued)
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Sensitivity and subgroup analyses
We performed sensitivity analyses by excluding outliers [44, 58] and one or more studies.
They did not have significant changes in the extent of pooled outcome measures. As a result,
we included all the studies for the meta-analysis. We performed subgroup analyses on the
basis of month period of follow-up after second-line ART initiation (less than 12 months, 12–
18 months, above 18 months); patient groups (children, adults, mixed age-groups); regions in
SSA (southern Africa, eastern Africa, western Africa, mixed regions of SSA); and type of sec-
ond-line ART (PI-based ART, ritonavir-boosted PI-based ART). Accordingly, the pooled esti-
mates of second-line ART failure were 19.0/100 PYs (95% CI: 15.0–22.0/100 PYs; I2 = 97.58%;
Table 2. (Continued)
References Year of
publication
Study
design
Study setting Patient
groups
Second-line
regimen
Sample
size
Number
with TF
PYs of
follow-up
Van Zyl et al
[58]
2011 CS South Africa Adults LPV/r-based 93 37 93
Wandeler et al
[59]
2014 FU South Africa, Zambia, Zimbabwe Adults PI-based 1256 122 3495
Wandeler et al
[60]
2012 FU Zambia and South Africa Adults LPV/r-based 2330 240 1884
Total 18, 550 2, 473 19, 988.45
Note: CS, cross sectional; FU, follow-up; RFU, retrospective follow-up; ATV/r, ritonavir-boosted atazanavir; PI/r, ritonavir-boosted protease inhibitor; LPV/r, ritonavir-
boosted lopinavir; PI, protease inhibitor; PYs, Person-years of follow-up; TF, treatment failure; SSA, sub-Saharan Africa.
https://doi.org/10.1371/journal.pone.0220159.t002
Fig 2. Forest pilot of proportion for second-line HIV treatment failure in SSA.
https://doi.org/10.1371/journal.pone.0220159.g002
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P<0.001) at 12–18 month period of follow-up after second-line therapy initiation; 19.0/
100PYs (95% CI: 14.0–23.0/100PYs; I2 = 0.0%) among children; and 18.0/100 PYs (95% CI:
14.0–23.0/100 PYs; I2 = 97.60%; P< 0.001) among patients in the southern SSA (Fig 3A–3D
and S3 Table).
Factors associated with second-line ART failure
The pooled estimate for factors associated with second-line HIV treatment failure revealed
that certain factors were influencing the failure rates. High baseline viral load (OR: 5.67; 95%
CI: 13.40–9.45); advanced clinical stage of HIV at baseline (OR: 3.27; 95% CI: 2.07–5.19); low
peak CD4 cell counts at baseline (<100 cells/mm3) (OR: 2.80; 95% CI: 1.83–4.29); and subop-
timal adherence to second-line therapy (OR: 1.92; 95% CI: 1.28–2.86) were patient factors
associated with the significantly increased occurrence of second-line ART failures (Table 3).
Different independent study reports also described depressive symptoms [23]; tuberculosis
co-treatment with HIV/AIDS [45]; traditional medicine use [23]; delayed second-line HIV
treatment initiation [25]; and younger age [53] as factors that favored second-line therapy fail-
ure. On the other hand, a study report indicated obesity [53] and elevated total bilirubin [53]
as factors that protected second-line ART failure.
Publication bias
Egger’s regression test did not show any evidence for publication bias among the included
studies (P = 0.0992, one-tailed). In addition, Begg’s correlation test did not also show any evi-
dence of publication bias (P = 0.154, one-tailed) (Fig 4).
Discussion
In this meta-analysis, the pooled estimate of proportion for second-line HIV treatment failure
was 15.0 per 100 PYs of follow-up. This evidence is in line with reports from several studies
that revealed a proportion of second-line HIV treatment failure as high as 25% [32, 65–69].
With this, the rate of second-line therapy failure among HIV-infected children was estimated
to be 19.0 per 100 PYs. Aligned with this finding, 19% of children treated with PI-based sec-
ond-line therapy in Thailand encountered treatment failures [70]. Another study conducted in
Thailand also reported up to 49% virological failure rates in children treated with second-line
therapies [71]. Additionally, an ART audit for pediatric patients in London indicated that 37%
of the patients achieved HIV-RNA VL less than 400 copies/ml [72]. Lack of VL monitoring,
insufficient early diagnosis of failure, and unstructured and inadequate adherence counseling
were the few reasons implicated for the increased treatment failure rates in children [73].
The pooled treatment failure rates before 12 months and 12–18 months of follow-up after
second-line therapy initiation were 17.0/100 PYs and 19.0/100 PYs, respectively. The failure
rate was 9.0/100 PYs after 18 months of follow-up. This indicated that a relatively sustained
virological response is expected after the 18 months of follow-up. Similarly, a multi-centered
study in Asia and Africa found that the most frequent experience of second-line therapy failure
(i.e., 250.0/1000 PYs) occurred during 6 to 11 months of follow-up compared to the 18 months
and more duration of follow-up (i.e., 212.0/1000 PYs) [6].
Subgroup analyses by regions revealed lower second-line HIV treatment failure rates in
western (11.0/100 PYs) and eastern (13.0/100 PYs) regions of SSA compared to the rate in
southern (18.0/100 PYs) region. These estimates are in line with the 19.6 million people living
with HIV in southern and eastern regions compared to the 6.1 million people living with the
infection in western and central Africa regions in 2017 [74]. Since a minimal failure rate can
naturally occur toward antimicrobial agents, an increased probability of failure might be
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expected in the southern/eastern regions of Africa with a higher HIV burden. Indeed, in the
presence of infection and antimicrobial agent use, there is always a natural phenomenon of
drug resistance and failure [75]. This phenomenon can also be accelerated with improper
infection control practices and suboptimal adherence to the ART [75]. In addition, two studies
indicated consistent findings with the second-line HIV treatment failure rates in southern
(19%) [76] and western/eastern regions (11.1%) [19].
High VL (� 5000 copies/ml) at second-line HIV treatment initiation increased the odds of
treatment failure (odds ratio (OR) 5.67; 95% CI: 3.40–9.45; P<0.0001). Patients who experi-
enced virologic failure with first-line therapy and switched to second-line therapy after 12
months were more likely to experience a further increase in VL as a potential indicator for sec-
ond-line therapy failure [77]. Several studies indicated that second-line therapy failure was
associated with higher baseline VL measurements [26, 78–84]. Patients who had an experience
of suboptimal adherence to second-line therapy were more likely to develop treatment failure
compared to patients with optimal adherence (OR 1.92; 95% CI: 1.28, 2.86; P = 0.0013). Several
published reports explained a relationship between suboptimal adherence to second-line
Fig 3. Forest pilots of proportion for second-line HIV treatment failure by subgroups. (a) Forest pilot describing
failure by months of follow-up. (b) Forest pilot describing failure by regions of SSA. (c) Forest pilot describing failure
by age group of participants. (d) Forest pilot describing failure by ritonavir boosting status of PI-based ART.
https://doi.org/10.1371/journal.pone.0220159.g003
Table 3. Pooled estimates of factors associated with second-line HIV treatment failure.
Factor OR (95% CI) Z statistic P-values
High VL at second-line therapy initiation 5.67 (3.40–9.45) 6.67 <0.0001
Advanced WHO clinical stage at baseline 3.27 (2.07–5.19) 5.06 <0.0001
Low CD4 cell counts (<100 cells/mm3) at baseline 2.80 (1.83–4.29) 4.75 <0.0001
Suboptimal adherence to second-line ART 1.92 (1.28–2.86) 3.20 0.0013
Note: VL, viral load; OR, odds ratio; ART, antiretroviral therapy; WHO, World Health Organization.
https://doi.org/10.1371/journal.pone.0220159.t003
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therapy and the increase in failure rates [6, 22, 26, 71, 79, 81, 85–88]. In addition, patients with
histories of suboptimal adherence to first-line therapy were also more likely to have suboptimal
adherence to second-line therapy [50, 89]. It could increase the odds of second-line HIV treat-
ment failure rate. This increased failure rate may also be linked to poor treatment adherence
resulting from the more frequent toxicities associated with second-line ART regimens [65].
An advanced clinical stage (stage III or IV) of HIV at the commencement of second-line
therapy increased the odds of treatment failure (OR 3.27; 95% CI: 2.07–5.19; P<0.0001). With
this, baseline CD4 cell counts of< 100 cells/ml were linked to increased odds of treatment fail-
ure (OR 2.80; 95% CI: 1.83–4.29; P<0.0001). Growing evidence relate the advanced HIV and
lower peak CD4 cell counts at baseline to the increased rates of failure with second-line therapy
[6, 69, 77, 87, 90].
Some of the included studies also reported that patients with lengthy delays in initiating sec-
ond-line therapy [25]; who were underweight [22]; who were on tuberculosis co-treatment
[45]; who had depressive symptoms [23]; who were with practice of herbal or traditional medi-
cine use [23]; and who were at younger age [53] had increased rates of treatment failure [63,
71, 77, 80, 90]. Although the relationship among depression, adherence and treatment failure
is yet to be fully investigated, more than one-third of HIV-infected patients with depressive
symptoms were found to have an elevated HIV-RNA VL in South Africa [91]. Patients with
higher depression rating scales, with higher HIV-RNA VL and at a younger age were indicated
to have increased patterns of ART missed doses [92]. A high probability of suboptimal adher-
ence to ART among alcohol users was also reported [93] which can contribute to the ART fail-
ure. Despite widespread concern about concurrent traditional medicine use and ART, yet
there is no sufficient evidence of whether traditional medicine use results in adverse effects or
interactions that could limit the effectiveness of the ART or not [94]. With regard to HIV-
tuberculosis co-treatment, suboptimal adherence to treatments was explained by a study
report [95] and this interpretation could be related to the outcome of ART.
Contrary to other studies, one of the included studies reports that obese or overweight
patients had a reduced proportion of failure to second-line ART [53]. Obese HIV patients
were found to have higher CD4 counts compared to normal-weight patients [96]. A higher
plasma concentration of second-line regimen containing darunavir-boosted with ritonavir
was revealed in obese patients [97]. The WHO recommended second-line therapies for HIV-
infection involve mainly ritonavir-boosted PI-based regimen. The ritonavir inhibits cyto-
chrome P450 enzymes to which many of the medications are substrate [98]. The ritonavir-
enzyme interaction can increase the plasma concentration of second-line therapy thereby
Fig 4. Funnel plot of standard error by logit event rate for publication bias.
https://doi.org/10.1371/journal.pone.0220159.g004
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protects treatment failure experience [99]. Although the relationship between elevated total
bilirubin and second-line therapy failure is not fully clear, up to one-third of patients treated
with atazanavir had elevated bilirubin as a marker of hepatotoxicity [100, 101]. Aligned with
this, a higher discontinuation rate of ritonavir-boosted atazanavir [101] and super-boosting of
lopinavir-ritonavir were linked with co-administration of a medication that inhibits hepatic
cytochrome P450 enzymes [102].
Although the overall sample size was large enough, there are some limitations to note. First,
the majority of data were derived from observational studies which resulted in a high degree of
heterogeneity and a range of potential biases. As a result, we have used a random-effects model
which is more appropriate in such anticipated heterogeneity. A series of subgroup analyses
were also considered to reduce the degree of heterogeneity and presented them in percentages
to indicate the extent of differences. Second, other additional potential explanations for sec-
ond-line therapy failures including medication toxicities and drug-drug interactions might
not have been adequately addressed. Third, we have included articles published only in the
English language and this could under-or over-estimate the pooled proportion of second-line
therapy failure in the SSA. Finally, the reporting of some variables pertaining to clinical and
programmatic follow-ups were inconsistent, limiting the conclusiveness of the pooled factors
associated with the second-line HIV treatment failure.
Conclusion
The pooled proportion of second-line HIV treatment failure experienced by HIV-infected
patients in SSA was found to be high. More common failure rates occurred at a 12–18 month
period of follow-up after second-line therapy start, in children, and in the southern region of
the SSA. Suboptimal adherence to second-line ART, higher HIV-RNA VL at baseline, lower
peak values for CD4 cells, and advanced WHO clinical stages were among the key factors that
have accelerated second-line HIV treatment failure in the setting. With this, prolonged delays
in switching prior therapy, tuberculosis co-treatment, and other patient factors including
younger age, depressive symptoms, underweight, and traditional medicine use were linked
with the occurrence of second-line treatment failure. Therefore, optimal second-line HIV
treatment approaches should critically consider immediate and aggressive VL suppression,
rapid immune recovery, and excellent adherence to the therapy. Together with these
approaches, more frequent clinical follow-ups and VL monitoring are recommended for the
HIV-infected patients in SSA that help in rapid identification and intervention of failure cases.
Finally, countries in the SSA should develop strategies and guidelines related to containment
of second-line HIV treatment including intensive adherence support and intervention as rou-
tine clinical practice especially for patients with slow response to the therapies.
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